EC approves PADCEV and KEYTRUDA combo for advanced urothelial cancer treatment

Astellas Pharma Inc. has announced a significant milestone in cancer treatment with the European Commission (EC's) approval of PADCEV (enfortumab vedotin) combined with KEYTRUDA (pembrolizumab). ... Read More